FLNA Modulators for Refractory FCDII and TSC Epilepsy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Epilepsy associated with focal cortical dysplasia type II (FCDII) and tuberous sclerosis complex (TSC) is refractory to existing treatments, with limited surgical options and significant side effects from everolimus, necessitating a need for novel therapeutic approaches to reduce or eliminate seizures and associated comorbidities.
Innovation Solution
Administration of FLNA modulators, such as PTI-125, to inhibit hyperphosphorylation of the tau protein and treat epilepsy by normalizing FLNA levels in dysmorphic neurons, as well as a method to determine Alzheimer's disease pathology through protein-protein complex analysis in lymphocyte preparations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical resection is performed to treat focal cortical malformations, then seizure control may be achieved, but the procedure is invasive and traumatic with 30-40% failure rate
Solution Approach 1:
The patent replaces the mechanical surgical intervention with a pharmacological approach using mTOR inhibitors (everolimus, rapamycin, sirolimus) that target the molecular pathway (mTORC1 hyperactivity) causing the malformations. This substitution eliminates the need for invasive surgery while addressing the root cause of seizure generation through biochemical modulation.
Solution Approach 2:
The patent changes the therapeutic parameter from physical removal of tissue to pharmacological modulation of molecular signaling. By altering the biochemical environment through mTOR inhibition, the patent aims to normalize neuronal development and reduce seizure frequency without the trauma of surgery.
2Reliability
If everolimus is administered at high doses to reduce seizure frequency, then seizure reduction is achieved in 40% of patients, but significant side effects occur and 60% show no improvement
Solution Approach 1:
The patent optimizes the dosing parameter of everolimus, transitioning from high-dose regimens to lower-dose formulations. This parameter adjustment aims to maintain therapeutic efficacy in seizure reduction while minimizing adverse effects, reflecting a balance between effectiveness and tolerability.
3Adaptability or versatility
If multiple anti-seizure drugs are tried to treat epilepsy, then comprehensive treatment coverage is achieved, but treatment complexity and failure rate increase
Solution Approach 1:
The patent extracts the common molecular pathway (mTORC1 hyperactivity) that underlies multiple different types of focal cortical malformations (FCD type II, TSC, STRADalpha deficiency). By targeting this unified pathway with mTOR inhibitors, the patent simplifies treatment from the complex approach of trying multiple different drugs to a focused therapy addressing the root cause.
Solution Approach 2:
The patent identifies a universal therapeutic mechanism (mTOR inhibition) that can treat multiple different etiologies of focal cortical malformations. This multi-functional approach allows a single drug class to address diverse conditions (FCD, TSC, STRADalpha deficiency) that share common molecular features, reducing treatment complexity while maintaining broad coverage.
Data Source
AI summary
In various aspects and embodiments the invention provides a method of treating epilepsy in a subject in need thereof, the method comprising providing to the subject an effective amount of an FLNA modulator. In various embodiments, the FLNA modulator is PTI-125 or kartogenin. In various embodiments, the epilepsy is epilepsy associated with focal cortical dysplasia (FCD) type II or tuberous sclerosis complex (TSC).